Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)

Authors not listed

Allergan · 2015

Abstract

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2015). Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study). <em>Allergan</em>. https://clinicaltrials.gov/study/NCT02462928
Vancouver
Anonymous. Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study). Allergan. 2015.
BibTeX
@misc{anon2015Safety, title = {Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)}, author = {Anonymous}, journal = {Allergan}, year = {2015}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings